...
首页> 外文期刊>Thoracic cancer. >EGFR T790M detection in formalin‐fixed paraffin‐embedded tissues of patients with lung cancer using RNA‐based in situ hybridization: A preliminary feasibility study
【24h】

EGFR T790M detection in formalin‐fixed paraffin‐embedded tissues of patients with lung cancer using RNA‐based in situ hybridization: A preliminary feasibility study

机译:EGFR T790M在肺癌患者的肺癌患者中使用RNA的原位杂交患者进行T790M检测:初步可行性研究

获取原文

摘要

Following drug resistance in patients with lung cancer treated by EGFR TKIs, a biopsy is required to obtain sufficient cancer tissue for T790M detection in order to select potential beneficiaries suitable for third-generation EGFR TKIs, such as osimertinib. The purpose of this study was to explore the feasibility of using a new in situ analysis technique based on RNA target sequences to detect EGFR T790M in lung cancer. A total of 28 formalin-fixed paraffin-embedded (FFPE) samples from 24 lung adenocarcinoma patients archived in Peking Union Medical College Hospital from 2015 to 2016 were collected. The BaseScope T790M detection technique by in situ hybridization on FFPE slides was used to analyze the mutation of EGFR T790M, and then the results were compared with the data acquired by Scorpions ARMS assay, which is the so-called gold standard for EGFR gene mutation testing. The sensitivity and specificity of the BaseScope T790M detection technique were preliminarily evaluated. Of the 28 FFPE specimens, the average proportion of T790M-positive cells was 35.78%?±?17.68% in 18 samples with EGFR T790M, confirmed by Scorpions ARMS assay, Compared with real-time PCR assay, the sensitivity and specificity of BaseScope T790M were all 100% in our cohort. BaseScope T790M assay could be completed on only one FFPE slide and the visualized molecular result overplayed with histomorphological information perfectly, so it may be the alternative method for EGFR T790M evaluation. BaseScope assay has potential clinical utility, and it will be necessary to carry out validation with a large number of cases. ? 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
机译:由于EGFR TKI治疗的肺癌患者的耐药性后,需要活检以获得足够的癌症组织进行T790M检测,以便选择适合于第三代EGFR TKI的潜在受益者,例如OSIMERTINIB。本研究的目的是探讨基于RNA靶序列使用新的原位分析技术的可行性,以检测肺癌中的EGFR T790M。收集了来自2015年至2016年北京联盟医院医院的24例血液型固定的石蜡嵌入式(FFPE)样本。通过在FFPE载玻片上原位杂交的BASESCOPE T790M检测技术用于分析EGFR T790M的突变,然后将结果与蝎子臂测定的数据进行比较,这是EGFR基因突变检测的所谓金标准。初步评估了底座T790M检测技术的敏感性和特异性。在28个FFPE标本中,T790M阳性细胞的平均比例为35.78%?±17.68%,18个样品中的18个样品,通过蝎子臂测定确认,与实时PCR测定,底座T790M的敏感性和特异性相比我们的队列全部100%。 BaseScope T790M测定可以仅在一个FFPE幻灯片上完成,并且可视化分子结果完美地用组织形态信息展现,因此可以是EGFR T790M评估的替代方法。 BaseScope测定具有潜在的临床效用,有必要在大量情况下进行验证。 ? 2019年的作者。中国肺部肿瘤集团和约翰瓦里和儿子澳大利亚发表的胸癌

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号